Navigation Links
Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
Date:6/19/2009

dification or additional methods may need to be developed, the success of which is not assured, due to possible future changes in the L-DOS47 formulation or manufacturing process, requirements of regulatory authorities, or other factors; the need to further upscale the manufacturing process for the Company's drug candidates and the risk that further upscaling may not be achieved within the timelines expected by the Company or at all; the need for regulatory approvals, which may not be obtained in a timely manner or at all; the need for clinical trials, the occurrence and success of which cannot be assured; intellectual property risks; marketing/manufacturing risks and partnership/strategic alliance risks, including Helix's dependency on KBI Biopharma Inc. and its other contractors, consultants and advisors, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; product liability risks; the effect of competition; the risk of technical obsolescence; and the risk of changes in business strategy or development plans. Such risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest Annual Information Form, MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at www.sedar.com, and in the Company's Form 20-F and other reports filed with the U.S. SEC from time to time (see www.sec.gov/edgar.shtml). Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should tho
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
2. Helix BioPharma to Present at the BioFinance 2009 Conference
3. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
4. Helix BioPharma Announces Q2 2009 Financial Results
5. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
6. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Announces Q1 2009 Financial Results
9. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
10. Helix BioPharma Corp. Announces Fiscal 2008 Results
11. Helix Biopharma Closes $11.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015  Susan Hedstrom, Executive Director of the ... dedicated to supporting research to advance the understanding ... that FPWR has received the organization,s largest donation ... contributed $1 million in support of the organization,s ... "Our gift signifies our tremendous ...
(Date:5/21/2015)... NOVATO, Calif. , May 21, 2015 /PRNewswire-USNewswire/ ... Orrin Hatch (R-UT) and Amy ... Product Extensions Now Accelerating Cures & Treatments, or ... 150 rare disease patient advocacy organizations, this bipartisan ... effective, and affordable medicines to rare disease patients ...
(Date:5/21/2015)... 2015 Patent Offering, The patent’s technology ... or therapeutic imaging within a body lumen (open space). ... having a low cost, single-use disposable illumination and camera ... October 18, 2013 and the patent approval was received ... physician to customize the lighting and magnification of the ...
(Date:5/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ... "2015 Global Survey on Flow Cytometry Adoption Trends" ... primary goal of this research is to analyze ... Key information the survey seeks to collect include ... predominantly used applications for flow cytometers, respondents, most ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2
... Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced ... Stroke (NINDS),National Institutes of Health (NIH) and Lixte ... in many common cancers, that,is a target of ... the treatment,of brain tumors., Dr. John S. ...
... BUDAPEST, Hungary, August 19 ChemAxon, a software,solutions ... 5.1 of their cheminformatics toolkits, Marvin & JChem. ... introduction of IUPAC name import,support for OLE 2 ... Marvin & JChem is a software suite of ...
... WELLESLEY, Mass., Aug. 19 Xceed Molecular, a ... announced that R&D Magazine has selected the company,s ... R&D 100 Award. Called,the Oscars of Invention by ... according to R&D, "a mark of excellence known ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents 2Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents 3ChemAxon Launches Marvin and JChem Version 5.1; Name to Structure Generation, OLE 2 and JavaScript Integration 2Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award 2
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... the tiniest organs in the body has shown to provide ... University of Bristol researchers and published in Nature Communications ... The carotid body a small nodule (no larger ... carotid artery appears to be a major culprit in ...
... condition called hypertrophic cardiomyopathy (HCM) found that the risk of ... greatest for those who developed this disease as infants with ... inborn errors of metabolism, a group of rare genetic disorders ... processes are disrupted. The findings will be published ...
... common fungus found living in, and on, many parts of ... humans unless it can breach the body,s immune defences, where ... as an opportunistic pathogen that can colonise and infect individuals ... the Society for General Microbiology,s Autumn Conference, gives us a ...
Cached Biology News:Size really does not matter when it comes to high blood pressure 2Risk factors help predict outcomes for children with rare heart condition 2Research identifies how mouth cells resist Candida infection 2
... is an enzyme that catalyzes the ... maltose, maltotriose, and dextrins. The,level of ... human body is of,clinical significance in ... and diabetes; plant and microbial a-amylases ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
Biology Products: